The Drug Discovery Chemistry Europe conference, held last week in Barcelona, brought together leading scientists in medicinal chemistry, chemical biology, and early drug discovery.

Prof. Carles Galdeano delivered a talk titled “From Exploiting Binding Sites on E3 Ligases to Developing Allosteric Modulators of the FBW7 E3 Ligase,” where he presented the group’s latest advances in targeting E3 ligases and expanding the therapeutic potential of allosteric modulation strategies.

Dr. Anna Sampietro presented a poster titled “Targeting the Keap1 E3 Ligase: PROTACs with Dual Mechanism of Action.” Her work showcases innovative approaches to designing PROTACs capable of engaging Keap1 through two complementary mechanisms, opening new perspectives in the field of targeted protein degradation.

The presence of the Galdeano Lab at Drug Discovery Chemistry Europe highlights the group’s ongoing contributions to cutting-edge research in chemical biology and targeted therapeutics.